2nd ESTRO Forum 2013 adjuvant intent. We compared plans with Foward Planning -IMRT (FP-IMRT) adjusted to the delineated breast volume with two other plans without the breast delineated (one with standard tangential beams with wedges and another with FP-IMRT). The ACOSOG Z0011 trial showed the non inferiority of the irradiation of axillary levels I and II (included in the irradiated volume when using standard tangential beam radiotherapy to the breast) when compared with axillary dissection of the same levels, in selected patients with breast cancer. Materials and Methods: We analyzed data from 40 patients undergoing radiotherapy after breast conserving surgery, with a negative sentinel node biopsy. The patients were submitted to a CT for virtual simulation with 3mm slice. The data from the CT were doubled. In one CT, 2 dosimetry plans were done: one with conventional RT with tangential beams with wedges (2-3 segments were added if necessary to achieve dose homogeneity) and another with FP-IMRT. On the other CT data, target volumes were delineated: breast CTV and PTV (expansions of 10 mm were made for all directions except for the posterior one, which was 7 mm), and a plan was calculated using the FP-IMRT technique, adjusted to the PTV. We then outlined the axillary levels I and II, for analysis, on one CT data and copied it to the other. Mean dose (Dmean) and V95 were evaluated for axillary levels I and II. The Conformity Index (CI) of the PTV was also analysed. Results: Both V95 and Dmean for axillary level I were higher in the standard tangential beams with wedges technique and in the FP-IMRT technique without the breast volume delineated. When compared with these plans, the plan adjusted to the breast PTV achieved an inferior V95 value to axillary level I. When evaluating the axillary level II, these differences were more pronounced. We found a higher CI value in the plan adjusted to the breast target volume. Conclusions: We found a higher conformity index to the breast target volume using the FP-IMRT technique with the breast target volumes delineated, and a lower V95 for the axillary levels evaluated. This shows that when conforming the dose to the breast alone the unintended irradiation of the axilla is lower. Although a higher V95 was achieved with the standard tangential breast irradiation with wedges, it happens at the expenses of a lower conformity index to the breast volume, and this technique has shown a higher rate of skin toxicity, which lead to being less used. We conclude that the delineation of axillary levels I and II is mandatory when there is the need to irradiate them, and the information obtained by the sentinel node biopsy is therefore important to the radiotherapy treatment. Purpose/Objective: Treatment of locally-advanced rectal cancer with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision has led to better results in sphincter-preservation and local recurrence rates in the last years. Achievement of a pathologic complete response (ypT0N0) after nCRT consistently associates to improved disease free and overall survival. However, no clinical or genetic predictorsof complete response are currently available which allow patient stratification and personalization of therapeutic strategies. Among the multiple pathways involved in CRT resistance, inflammatory response has been demonstrated to mediate both microenvironmental resistance to radiation damage. To evaluate the role of functional polymorphisms of inflammatory response genes (NF-kB, Cox-1, Cox-2,IL-1beta) in pathological response to nCRT in rectal cancer.
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Materials and Methods:
We included patients with locally advanced rectal cancer treated with nCRT (capecitabine, 3D pelvic radiotherapy, with TD 50.4 Gy) at asingle center. Genomic DNA was obtained from peripheral blood or paraffin-embedded non-tumor tissue. The following polymorphisms were analyzed with Taqmanbased qPCR: rs28362491(NF-Kβ), rs1213266 (COX-1), rs5789 (COX-1), rs20417 (COX-2), rs5275 (COX-2),rs16944 (IL-1β) and rs1143627 (IL-1β).
Association between genotypes and rectal cancer outcome was analyzed with logistic regression models (SNPstatssoftware). Results: 159 patients have been included; Patient characteristics: median age 65 years, 104%males, 55% female. 95% of population had Karnofsky 90-100%; stages IIA (27%), IIIA(4%), IIIB (25%), IIIC (45%). Abdominoperineal resection was practiced in 30% and lower anterior resection in 70% of cases.Surgery included complete mesorectal excision in 78% of patient population.Adjuvant chemotherapy was administered in 88% of them. Complete pathological response (pCR) rate was 18% and nonresponse in 20%. With a median follow-up of 44 months (range: 11-93), only 30 patients have recurred with local and/ormetastatic disease. Overall survival was 85,4% and desease free survival 81%.Univariate analysis shown statistically significant impact of NFkB associated to pCR and OS. Distribution of genotypic and allelic frequencies for the seven polymorphisms was similar to those observed in European populations. Conclusions: Our work is the first that analyze the relation between inflammation gene polymorphisms and response to nCRT in rectal cancer treatment. We did not find significant association between the genetic polymorphisms (s1213266, rs5789, rs20417, rs5275, rs16944, rs1143627) and the pathological response, but we observed impact of NF-Kb in relation between pathological response and overall survival. We also observed statistically significant relationship between performance status and treatment response. Patients with 100-90% Karnofsky have cPR or quasi complete pathological response to nCRT. 
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Materials and Methods:
38 patients with confirmed diagnosis of LARC (cT3-4 or cN+) were prospectively studied with 18F-FDG PET/CT before and after neoadjuvant therapy (NAT). Total mesorectal excision (TME) was programmed 6 weeks after NAT followed by an expert histopathological analysis of the surgical specimen. Baseline variables and previously identified cutoff values of pre-NAT (SUVmax PRE ≥ 6), post-NAT (SUVmax POST < 2), absolute (?SUVmax ≥ 4) and percentage reduction (?SUVmax ≥ 65%) of the baseline maximum FDG standardized uptake value (SUVmax) criteria were applied to differentiate metabolic tumor responders from non-responders. These features were correlated with disease-free survival (DFS) and overall survival (OS visceral metastasis were excluded from the study. All the patients were treated in two phases to a total dose of 5940cGy. Phase I CTV (treated to a dose of 45Gy in 25 fractions) was generated by expanding the GTV primary cranio-caudally by 4cm and laterally to include electively, the corresponding level mediastinal nodes. Phase II CTV was generated by expanding the GTV by 2cm craniocaudally and 1cm radially. Bilateral supraclavicular regions were electively included for supracarinal lesions. ITV was generated by expanding the CTV by 0.5cm which was then expanded by 0.5cm to yield PTV. IG-RA plans consisted of 2 conformal arcs with a high priority to reduce lung V20, mean lung dose and heart dose. The set-up was verified by daily KV imaging as well as thrice weekly CBCT with oral barium. Chemotherapy consisted of 4-6 cycles of weekly cisplatin 40mg/m2. Results: The median age of patients was 53 yrs (43-72).The median length of involvement of esophagus was 6cm with 80% of the lesions in the upper and middle third. 37/41(90%) patients completed planned chemotherapy with atleast 4 cycles of cisplatin and 40/41 patients completed full dose of radiotherapy. 4/41 (10%) patients required tube feeding, 2/41 (5%)patients required hospital admission for supportive care but none of the patients had grade IV hematological toxicity during treatment. Endoscopy at 8 weeks post treatment was performed in 38/41 patients of whom 20 (53%) had CR,16 (42%) had PR and 2 (5%) had stable disease locally. With a median follow up of 15 (6-20) months, 18/41(44%) patients are alive at last follow-up of which 13 (32%) are disease free with no dysphagia, the 1 and 2 year overall survival are 70% and 42% respectively and median survival of 13.5 months. 3/18 (16%)alive patients have post radiotherapy stricture requiring occasional dilatations. Unfortunately none of the patients underwent salvage surgery because of various medical and social reasons. After analyzing KV image datasets, the modal corrections applied for bone matching was 0.1cm (vertical),0.2cm (lateral and 0.2cm longitudinal. The analysis of CBCT data sets showed that the ITV and PTV margins of 0.5cm each were found to be adequate with current imaging protocol. Conclusions: Image guided volumetric modulated arc therapy to a dose of 60Gy with concurrent weekly cisplatin is a feasible treatment option for locally advanced inoperable squamous cell carcinoma of thoracic esophagus with low acute and late toxicity and with promising early clinical outcomes. The ITV and PTV margins of 0.5cm were found to be adequate only with image guidance. Purpose/Objective: VEGFR, EGFR, Cox-2 and p53 stimulates key processes involved in tumor growth, progression and proliferation, and are important targets for cancer therapeutics. Ki-67 is a marker of tumor activity.The prognostic and predictive value of these novel biomolecular markers expression in association with proliferation in selecting targeted agents is currently unknown.The purpose of this study was to measure co-expression of EGFR, VEGFR, Cox-2, p53 and Ki67 proteins in pre-treatment tumor biopsies of rectal cancer patients treated with neoadjuvant treatment and to correlate expression with clinical outcome. Materials and Methods: EGFR,VEGFR, Cox-2, p53 and Ki67 coexpression was measured using immunohistochemistry quantitative image analysis. Ki67% activity (positive ≥90%) was quantified within EGFR, VEGFR, Cox-2 and p53 tumor in high versus low expression. Cox proportional hazards models were used to explore associations between the tumor markers and disease-free survival (DFS). Results: 38 pre-treatment tumors were analyzed. Patients median follow-up was 69.3 months (range,4.5-92) . Onunivariate analysis, high Ki67% activity in VEGFR (HR 4.06 [1.14, 14.43] , p =0.03), 13 .45], p = 0.03); and p53 (HR 4.15 [1.07, 16 .07], p Z 0.04) high expression tumors was associated with worse DFS. On multivariate analysis, only high Ki67% activity in VEGFR high expression tumors remained statistically significant forDFS (HR 4.07 [1.14, 14.3] , p = 0.04). Conclusions: High Ki67% activity in VEGFR high expression tumors are associated with worse DFS in patients with rectal cancer treated with induction CT followed by pelvic CRTand surgery. Determination of the optimal diagnostic cut-off level for this novel biomarker association should be explored. Evaluation within a clinical trial will be required to determine whether patients could benefit from an VEGFR targeted therapeutic agent. 2009 and 2010 . Seven of these patients (46.7%) relapsed; two patients (13.3%) had infield recurrence and five (33.3%) experienced distant recurrence. All patients were treated with chemoradiation (as per the NCRI UK SCOPE trial protocol but not all treated witihin the trial) and received conformal radiotherapy of 50Gy in 25 fractions to the PTV. This PTV was derived from a CTV based on a CT scan with information from un-registered PET-CT and endoscopic ultrasound. Retrospectively, deformable image registration was performed (Mirada RTx, Mirada Medical, Oxford, UK) between the original planning CT and the PET-CT images. Tumour volumes were contoured on the PET-CT images and projected onto the original planning CT. In addition, for local relapse patients, deformable image registration was carried out between the planning CT and the relapse CT images. (Figure 1 ) The site of relapse was contoured and projected onto the planning CT. This enabled comparison of the site of relapse relative to the planning CT and PET-CT volumes and the dose received by each volume to evaluate tumour coverage. Dosimetric analysis was undertaken. (Table 1 ) Results: Deformable registration (not rigid body) was necessary to accurately transfer relapse CT derived contours to the planning CT as the patients typically had different curvature of the spine and oesophagus in the PET-CT and diagnostic relapse CT compared to planning CT. Of the two local relapses, one was within the PET-CT volume whilst the other was in the high dose penumbra (small cell oesophageal cancer). This patient died of distant metastatic disease. Relapse Tumour Volume n-a 8.36 n-a n-a n-a n-a 47.45 
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Conclusions:
Deformable image registration is a valuable tool that allows relapse CT data to be compared accurately to the original planning CT and therefore determine if current target definition is adequate. Investigation of a larger cohort is required to confirm these observations by including this this procedure in the analysis of future
